There were 1,781 press releases posted in the last 24 hours and 358,379 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image